NCT02262689 - To Evaluate Effects of GSK2256294 on Pulmonary Artery Pressure in Healthy Volunteers Under Normoxic and Hypoxic Conditions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 8, 2015

Primary Completion Date

April 24, 2015

Study Completion Date

April 24, 2015

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK2256294

GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg

DRUG

Placebo

Matched Placebo will be supplied as gelatin capsule to be administered orally

Trial Locations (1)

GSK Investigational Site, Baltimore